NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 207 filers reported holding NEKTAR THERAPEUTICS in Q1 2017. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $10,143,000 | +142.4% | 95,451 | +36.2% | 0.43% | +96.4% |
| Q4 2017 | $4,184,000 | -58.8% | 70,062 | -83.4% | 0.22% | -57.0% |
| Q3 2017 | $10,154,000 | +25.2% | 423,100 | +2.0% | 0.51% | +16.6% |
| Q2 2017 | $8,109,000 | +200.0% | 414,800 | +260.2% | 0.44% | +227.6% |
| Q1 2017 | $2,703,000 | +6.6% | 115,150 | -44.3% | 0.13% | -20.2% |
| Q4 2016 | $2,535,000 | +28.0% | 206,600 | +14.3% | 0.17% | -1.2% |
| Q3 2015 | $1,981,000 | +18.3% | 180,716 | +24.6% | 0.17% | -0.6% |
| Q2 2013 | $1,675,000 | – | 145,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |